CollPlant Biotechnologies Expands North American Operations and Reports Q3 2025 Results

TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off Collplant Holdings ( (CLGN) ) just unveiled an announcement. CollPlant Biotechnologies reported its third-quarter financial results for 2025, highlighting significant advancements and strategic initiatives. The company announced the expansion of its rhCollagen and BioInk sales in North America through a new logistics partnership and commercial leadership, aiming to enhance its market presence. Recent developments include a collaboration with Mayo Clinic to create a humanized bioprinted skin model, and a comparative study showing its bioink, Collink.3D™, outperformed a leading extracellular matrix in tissue formation. Additionally, CollPlant is implementing cost-reduction measures and prioritizing its collaboration with AbbVie and the development of its dermal filler product. The company is also expanding its international distribution network for its tendon-repair product, Vergenix™ STR, into new markets. The most recent analyst rating on (CLGN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page. Spark’s Take on CLGN Stock According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral. Collplant Holdings’ overall stock score is primarily impacted by its poor financial performance, characterized by significant revenue and cash flow declines and negative profit margins. Technical analysis also indicates a bearish trend, while valuation metrics highlight the company’s unprofitability. These factors collectively suggest a high-risk investment without immediate signs of improvement. To see Spark’s full report on CLGN stock, click here. More about Collplant Holdings CollPlant Biotechnologies is a company operating in the regenerative and aesthetics medicine industry, focusing on developing innovative technologies and products based on its non-animal-derived rhCollagen for tissue regeneration and medical aesthetics. Average Trading Volume: 96,038 Technical Sentiment Signal: Strong Sell Current Market Cap: $28.23M Learn more about CLGN stock on TipRanks’ Stock Analysis page.